Radiotherapy for Glioblastoma in the Elderly  

Oleh:

Keime-Guibert, Florence ; Chinot, Olivier ; Taillandier, Luc ; Cartalat-Carel, Stephanie ; Frenay, Marc ; Kantor, Guy ; Guillamo, Jean-Sebastien ; Ericjadaud ; Colin, Philippe ; Bondiau, M. Pierre-Yves ; MeneY, Philippe ; Loiseau, Hugues ; Bernier, Valerie ; Honnorat, jerome ; Barrie, Maryline ; Mokhtari, Karima ; Mazeron, Jean-Jacques ; Bissery, Anne ; Delattre, jean-Yves

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 356 no. 15 (Apr. 2007), page 1527.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2007.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

BACKGROUND There is no community standard for the treatment of glioblastoma in patients 70 Fcc years of age or older. We conducted a randomized trial that compared radiotherapy As and supportive care with supportive care alone in such patients. METHODS Patients 70 years of age or older with a newly diagnosed anaplastic astrocytoma or glioblastoma and a Karnofsky performance score of 70 or higher were randomly Ur assigned to receive supportive care only or supportive care plus radiotherapy (focal radiation in daily fractions of 1.8 Gy given 5 days per week, for a total dose of 50 Gy).The primary end point was overall survival; secondary end points were progression free survival, tolerance of radiotherapy, health-related quality of life, and cognition. RESULTS We randomly assigned 85 patients from 10 centers to receive either radiotherapy and supportive care or supportive care alone. The trial was discontinued at the first interim analysis, which showed that with a preset boundary of efficacy, radiotherapy de and supportive care were superior to supportive care alone. A final analysis was carried out for the 81 patients with glioblastoma (median age, 73 years; range, 70 to 85). At a median follow-up of21 weeks, the median survival for the 39 patients who received radiotherapy plus supportive care was 29.1 weeks, as compared with 16.9 *p weeks for the 42 patients who received supportive care alone. The hazard ratio for S death in the radiotherapy group was 0.47 (95% confidence interval, 0.29 to 0.76; P=0.002). There were no severe adverse events related to radiotherapy. The results of quality-of-life and cognitive evaluations over time did not differ significantly between the treatment groups. CONCLUSIONS Radiotherapy results in a modest improvement in survival, without reducing the quality oflife or cognition, in elderly patients with glioblastoma. (ClinicaITrials.gov number, NCT00430911.)

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali